Skip to content
E3 · Other / exploratoryReviewPEM requiredNarrative reviewPeer-reviewed
Standard · 3 min

The gastrointestinal microbiota in the development of ME/CFS: a critical view and potential perspectives.

Stallmach, Andreas, Quickert, Stefanie, Puta, Christian et al.

Frontiers in immunology2024DOIPubMed

Design
Narrative review
Participants
Not reported
PEM required
Yes
Case definition
Not stated in the abstract

Quick Summary

This review examines whether changes in gut bacteria might play a role in ME/CFS, particularly in cases that develop after infections like COVID-19. The authors found that many ME/CFS patients do show differences in their gut bacteria compared to healthy people, and these changes might trigger immune and inflammatory problems. However, the review concludes that current research hasn't proven that gut bacteria changes actually cause ME/CFS—only that they often occur together.

Why It Matters

Understanding whether gut microbiota changes contribute to ME/CFS could identify new therapeutic targets for this debilitating condition lacking approved treatments. If dysbiosis is causally implicated, microbiota-modulating interventions (prebiotics, probiotics, dietary modifications) could potentially become evidence-based treatment options, offering hope to patients currently managing symptoms without specific medical therapies.

Observed Findings

What the study reports it measured.

  • Alterations in gastrointestinal microbiota composition are documented in ME/CFS patient cohorts
  • Microbial changes are associated with immunological and inflammatory pathway abnormalities in ME/CFS
  • Proposed mechanisms include intestinal barrier dysfunction, microbial translocation, and increased oxidative stress
  • Dysbiosis frequently co-occurs with ME/CFS symptoms, but causality remains unestablished
  • Most studies combine heterogeneous clinical presentations (IBS, fatigue, post-infection syndromes) in poorly characterized populations

Inferred Conclusions

What the authors interpret from those results.

  • Dysbiosis may represent a modifiable factor in ME/CFS pathophysiology worthy of therapeutic investigation
  • Microbiota-modulating strategies warrant clinical trial testing as potential treatments for ME/CFS and other PAIS
  • Robustly designed longitudinal studies with well-characterized, homogeneous patient populations are needed to establish causality
  • Drawing on mechanisms from other gastrointestinal diseases, microbiota modulation offers a rational therapeutic avenue despite current uncertainty about causation

Remaining Questions

  • Does dysbiosis cause ME/CFS, or is it a consequence of the disease and its associated lifestyle changes?
  • Which specific microbial alterations, if any, are causally linked to ME/CFS pathophysiology versus merely associated?
  • What microbiota-modulating interventions (probiotics, prebiotics, dietary approaches) would be most effective, and in which ME/CFS patient subgroups?
  • How do microbiota changes relate to post-exercise malaise (PEM) and other cardinal ME/CFS features mechanistically?

What This Study Does Not Prove

This review does not establish that gut microbiota changes cause ME/CFS—only that associations exist in some patient populations. The authors specifically highlight that current evidence cannot distinguish between dysbiosis as a primary driver versus a consequence of ME/CFS pathology or illness-related behavioral changes. The heterogeneous study populations and poorly defined patient cohorts limit any definitive conclusions about causality.

Explore further

About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →

Cite this study

The first block is for the primary paper and is the citation you should use in research work. The atlas-snapshot line only applies if you are specifically referring to this atlas’s reading of the paper on the date shown.

Primary citation

Stallmach, Andreas, Quickert, Stefanie, Puta, Christian, & Reuken, Philipp A (2024). The gastrointestinal microbiota in the development of ME/CFS: a critical view and potential perspectives.. Frontiers in immunology. https://doi.org/10.3389/fimmu.2024.1352744

BibTeX

@article{mecfsatlas-stallmach-2024-gastrointestinal-microbiota,
  author  = {Stallmach, Andreas and Quickert, Stefanie and Puta, Christian and Reuken, Philipp A},
  title   = {The gastrointestinal microbiota in the development of ME/CFS: a critical view and potential perspectives.},
  journal = {Frontiers in immunology},
  year    = {2024},
  doi     = {10.3389/fimmu.2024.1352744},
  note    = {PubMed: 38605969},
  url     = {https://www.mecfsatlas.com/evidence/stallmach-2024-gastrointestinal-microbiota},
}

Atlas snapshot reference

ME/CFS Atlas. Generator v1 / Scanner v1.4 / policy v0.1. Accessed 2026-11-14. https://www.mecfsatlas.com/evidence/stallmach-2024-gastrointestinal-microbiota

Contribute

Private, reviewed by a human. Not a public comment thread.